0001209191-22-051675.txt : 20220930
0001209191-22-051675.hdr.sgml : 20220930
20220930174211
ACCESSION NUMBER: 0001209191-22-051675
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220928
FILED AS OF DATE: 20220930
DATE AS OF CHANGE: 20220930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kulkarni Samarth
CENTRAL INDEX KEY: 0001682019
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 221285187
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-28
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682019
Kulkarni Samarth
C/O CRISPR THERAPEUTICS, INC.
105 W FIRST STREET
BOSTON
MA
02127
1
1
0
0
Chief Executive Officer
Common Shares
2022-09-28
4
M
0
25000
16.21
A
315279
D
Common Shares
2022-09-28
4
S
0
23200
64.5782
D
292079
D
Common Shares
2022-09-28
4
S
0
1800
64.97
D
290279
D
Stock Option (Right to Buy)
16.21
2022-09-28
4
M
0
25000
0.00
D
2027-05-03
Common Shares
25000
33333
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.95 to $64.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.95 to $64.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2022-09-30